Mediti Pharma

Mediti Pharma Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Mediti Pharma General Information


Developer of drugs designed to treat Alzheimer's disease. The company's drugs help to identify and cure early symptoms of the disease such as hallucinations, delusions and aggression, enabling healthcare providers to improve the lives of Alzheimer's disease patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Montreal, Quebec
  • Canada
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mediti Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 20-Jun-2016 Completed Clinical Trials - Phase 2

Mediti Pharma Executive Team (2)

Name Title Board Seat Contact Info
Ivan Shaw Chief Executive Officer
Mark Cipriano Chief Financial Officer

Mediti Pharma Board Members (3)

To view Mediti Pharma‘s full board member team, request access »
Name Representing Role Since
Daniel Parera TVM Capital Life Science Board Observer 000 0000
Luc Marengère Ph.D TVM Capital Life Science Board Member 000 0000

1 Former Board Member

Mediti Pharma Investors (1)

To view Mediti Pharma‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial